While clinical investigation is ongoing, and these drugs will have to stand the test of randomized trials, the path of discovery may already be considered a success story: The development of these inhibitors and their introduction into clinical testing were a direct consequence of fundamental research efforts that discovered the Menin–KMT2A interaction as a dependency and therapeutic opportunity in these leukemia subtypes. Here, MEN1 is linked to leukemia.